Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Dermatologic 2Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 123Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67abiraterone 51atezolizumab 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39darolutamide 39Sorafenib 39apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × etaracizumab × Genitourinary × Clear all
NCT00072930 2008-01-15

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

MedImmune LLC

Phase 2 Completed
150 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡